Velcade abstracts to be presented at ASH meeting
Publicado: Jue Dic 03, 2009 10:54 pm
Velcade abstracts to be presented at ASH meeting
Fuente Smart-Brief IMF
http://investor.millennium.com/phoenix. ... highlight=
"Millennium: The Takeda Oncology Company said almost 200 abstracts have been accepted for presentation at the annual meeting of the American Society of Hematology, being held Dec. 5 to 8. The abstracts include data on Velcade as a foundation of therapy for multiple myeloma patients, an update on the survival benefit of Velcade as a front-line therapy and the cost-effectiveness of Velcade in treating myeloma patient"
saludos
Traducion:
http://www.translate.google.es/translat ... l=en&tl=es
Fuente Smart-Brief IMF
http://investor.millennium.com/phoenix. ... highlight=
"Millennium: The Takeda Oncology Company said almost 200 abstracts have been accepted for presentation at the annual meeting of the American Society of Hematology, being held Dec. 5 to 8. The abstracts include data on Velcade as a foundation of therapy for multiple myeloma patients, an update on the survival benefit of Velcade as a front-line therapy and the cost-effectiveness of Velcade in treating myeloma patient"
saludos
Traducion:
http://www.translate.google.es/translat ... l=en&tl=es